Skip to main content
Menu

Posts tagged with "Diabetes and Obesity"

  • Clinical Trials

    Zafgen Wins Another Round

    Since I’ve been following the progress of Zafgen and their unusual drug candidate on the blog, I wanted to note that it just resoundingly passed another Phase II trial. This one was in patients who’ve gained weight to due hypothalamic injury. The Phase III is in the works. Zafgen’s compound is one that most of… Read More
  • Diabetes and Obesity

    Daiichi Sankyo Will Pay You A Million Dollars

    Daiichi Sankyo is apparently crowdsourcing ideas for anti-obesity drug discovery. See this page at NineSigma. The requirements are that the submitted idea: Must be a new anti-obesity drug candidate or drug target Exhibit superior anti-obesity drug efficacy or a better safety profile than existing drugs (phentermine/topiramate, lorcaserin, orlistat) Read More
  • Diabetes and Obesity

    A New Effect From JAK Inhibition

    Here’s an interesting paper for people into metabolic disease: the authors report that JAK1/3 inhibitors (such as ​tofacitinib) seem to cause human adipocytes to convert from their normal phenotype into brown fat, a different beast altogether. Brown adipocytes are thermoregulators, and burn off lipids at an impressive rate. Many are the the… Read More
  • Business and Markets

    Novo Nordisk Braves the Obesity Market

    Everyone thinks of Novo Nordisk as a diabetes company (and that they are), but they’re willing to use their expertise in related areas. And if you know a lot about insulin and blood sugar regulation, you may also end up knowing a fair amount about appetite and satiety signaling in the gut. The company has… Read More
  • Diabetes and Obesity

    Diabetes Progress

    There have recently been some welcome developments in diabetes therapy, both Type I and Type II. For the latter, there’s an interesting report of a metabolic uncoupling therapy in Nature Medicine. Weirdly, it uses a known tapeworm medication, niclosamide (specifically, the ethanolamine salt). It’s toxic to worms by that same mechanism.… Read More
  • Diabetes and Obesity

    Reversal of Type II Diabetes May Be Possible

    Here’s some big news: Ron Evans and co-workers at Salk report that treatment with the growth factor FGF1 appears to reverse type II diabetes in mice. (Article in Science Daily on this study here). Evans has been working in this field (diabetes, insulin sensitivity, and related areas like growth factors and nuclear receptors) for a… Read More
  • Business and Markets

    Zafgen’s Epoxide Pays Its Way

    I’ve written here before about Zafgen, a small startup targeting obesity therapy with an unusual covalent epoxide drug candidate. Last fall they cleared Phase II, and now they’re going public. Bruce Booth, whose firm has been the VC muscle behind the company, has an overview of how things have worked here. It’s a good read… Read More
  • Diabetes and Obesity

    Speaking of Polyphenols. . .

    Yesterday’s mention of “nightmare polyphenols” prompted a reader to ask about the one in this paper. That’s it over there at the left, and yeah, that sure is a polyphenol. In fact, it’s a chaetochromin, a family of mycotoxins originally isolated from moldy rice. The paper doesn’t say anything about its stereochem… Read More
  • Biological News

    Ces3 (Ces1) Inhibition As a Drug Target

    Update: the nomenclature of these enzymes is messy – see the comments. Here’s another activity-based proteomics result that I’ve been meaning to link to – in this one, the Cravatt group strengthens the case for carboxylesterase 3 as a potential target for metabolic disease. From what I can see, that enzyme was first identifi… Read More
  • Biological News

    Irisin and Metabolism – A New Target Emerges

    Here’s something for metabolic disease people to think about: there’s a report adding to what we know about the hormone irisin, secreted from muscle tissue, that causes some depots of white adipose tissue to become more like energy-burning brown fat. In the late 1990s, there were efforts all across the drug industry to find beta-3… Read More